IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Howard Capital Management Inc.

Howard Capital Management Inc. lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 4.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,147 shares of the medical research company’s stock after acquiring an additional 54 shares during the period. Howard Capital Management Inc.’s holdings in IQVIA were worth $225,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. FMR LLC lifted its stake in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares during the period. Impax Asset Management Group plc lifted its stake in shares of IQVIA by 9.7% in the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after acquiring an additional 157,809 shares during the period. Nordea Investment Management AB lifted its stake in shares of IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of IQVIA by 3.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock worth $290,545,000 after acquiring an additional 39,772 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at IQVIA

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the purchase, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ? increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on IQV shares. Robert W. Baird cut their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, January 21st. UBS Group cut their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Deutsche Bank Aktiengesellschaft cut their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Finally, The Goldman Sachs Group cut their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average price target of $251.22.

IQVIA Stock Down 1.9 %

IQVIA stock opened at $190.98 on Wednesday. The firm has a market cap of $33.63 billion, a PE ratio of 25.46, a P/E/G ratio of 1.99 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm’s 50 day moving average price is $199.41 and its two-hundred day moving average price is $215.63. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.